[Cytomegalovirus and other herpes virus infections in systemic diseases]

Presse Med. 2010 Jan;39(1):34-41. doi: 10.1016/j.lpm.2009.04.005. Epub 2009 May 15.
[Article in French]

Abstract

Reactivation of Herpesviridae is well known among transplant patients, but has not been sufficiently studied in patients who receive immunosuppressive treatment for systemic inflammatory diseases. CMV infection seems relatively rare; it is easily diagnosed by real-time PCR, a fast and reliable diagnostic tool. CMV disease is most often manifested in the form of lung disease, hepatitis, or colitis. The highest risks are associated with steroid or cyclophosphamide boluses and methotrexate. Prophylactic treatment cannot be recommended in clinical practice. The utility of monitoring viremia and of preemptive therapy must be evaluated. Herpes zoster is the most frequent viral infection in systemic diseases. Most immunosuppressive treatments, except methotrexate, promote its occurrence. Visceral involvement is quite rare, and outcome almost always favorable. Prophylactic treatment cannot be recommended.

Publication types

  • English Abstract
  • Review

MeSH terms

  • Adrenal Cortex Hormones / adverse effects
  • Cytomegalovirus / physiology
  • Cytomegalovirus Infections* / diagnosis
  • Cytomegalovirus Infections* / drug therapy
  • Cytomegalovirus Infections* / etiology
  • Cytomegalovirus Infections* / virology
  • Herpes Zoster* / diagnosis
  • Herpes Zoster* / drug therapy
  • Herpes Zoster* / etiology
  • Herpes Zoster* / virology
  • Herpesvirus 3, Human / physiology
  • Humans
  • Immunocompromised Host*
  • Immunosuppressive Agents / adverse effects
  • Polymerase Chain Reaction
  • Virus Activation

Substances

  • Adrenal Cortex Hormones
  • Immunosuppressive Agents